{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:53:33Z","timestamp":1788324813450,"version":"build-2803163510"},"reference-count":26,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Malignant mesothelioma has a poor prognosis and limited therapeutic options. C-ERC\/mesothelin is highly expressed in mesotheliomas and is a potential target for radioimmunotherapy (RIT). This study evaluated the radiolabeled anti-C-ERC\/mesothelin antibody mAb 22A31 as a therapeutic agent. Methods: C-ERC\/mesothelin expression in mesothelioma cell lines was assessed by Western blotting, and the specific binding of 125I-labeled mAb 22A31 was examined. Biodistribution of 111In-labeled mAb 22A31 was evaluated in a mesothelioma cell line, MSTO-211H tumor-bearing mice. The therapeutic efficacy of 90Y-labeled mAb 22A31 was evaluated in subcutaneous and pleural dissemination models. Results: mAb 22A31 showed specific binding considering the level of C-ERC\/mesothelin expression in each mesothelioma cell line. 111In-mAb 22A31 accumulated in tumors with minimal uptake in normal tissues. 90Y-mAb 22A31 significantly delayed the growth of subcutaneous tumors and improved survival in a pleural dissemination model. Conclusions: Radiolabeled mAb 22A31 specifically targeted C-ERC\/mesothelin and demonstrated therapeutic efficacy in a mesothelioma xerograph model. Therefore, 90Y-mAb 22A31 is a promising RIT agent and supports the further development of C-ERC\/mesothelin-targeted therapy for mesothelioma.<\/jats:p>","DOI":"10.3390\/ph19030501","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:12:26Z","timestamp":1773853946000},"page":"501","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radioimmunotherapy for Malignant Mesothelioma Targeting C-ERC\/Mesothelin"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2421-7397","authenticated-orcid":false,"given":"Hirofumi","family":"Hanaoka","sequence":"first","affiliation":[{"name":"Graduate School of Medicine, Gunma University, 3-39-22 Showa-machi, Maebashi 371-8511, Japan"},{"name":"Near InfraRed Photo-ImmunoTherapy Research Institute, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Gunma University, 3-39-22 Showa-machi, Maebashi 371-8511, Japan"},{"name":"Radiopharmaceuticals for Advanced Diagnostic Imaging and Therapy R&D Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, 1881 East Rd., Houston, TX 77054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Maeda","sequence":"additional","affiliation":[{"name":"Immuno-Biological Laboratories Co, Ltd., 1091-1 Naka Aza-Higashida, Fujioka 375-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Segawa","sequence":"additional","affiliation":[{"name":"Immuno-Biological Laboratories Co, Ltd., 1091-1 Naka Aza-Higashida, Fujioka 375-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Oriuchi","sequence":"additional","affiliation":[{"name":"Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima 960-1295, Japan"},{"name":"Jyoban Hospital of Tokiwa Foundation, Kaminodai 57, Jyoban Kamiyunagaya, Iwaki 972-8322, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/0300891620926239","article-title":"Analysis of survival of patients with metastatic malignant pleural mesothelioma","volume":"107","author":"Okiror","year":"2021","journal-title":"Tumori"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Suraya, R., Nagano, T., and Tachihara, M. (2025). Recent advances in mesothelioma treatment: Immunotherapy, advanced cell therapy, and other innovative therapeutic modalities. Cancers, 17.","DOI":"10.3390\/cancers17040694"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90\u2013labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: A new target for cancer therapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1349-7006.2006.00246.x","article-title":"Novel ELISA system for detection of N-ERC\/mesothelin in the sera of mesothelioma patients","volume":"97","author":"Shiomi","year":"2006","journal-title":"Cancer Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: Ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Faust, J.R., Hamill, D., Kolb, E.A., Gopalakrishnapillai, A., and Barwe, S.P. (2022). Mesothelin: An immunotherapeutic target beyond solid tumors. Cancers, 14.","DOI":"10.3390\/cancers14061550"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1440-1827.2009.02344.x","article-title":"Establishment of a novel monoclonal antibody to human ERC\/mesothelin useful for the study and diagnosis of ERC\/mesothelin-expressing cancers","volume":"59","author":"Ishikawa","year":"2009","journal-title":"Pathol. Int."},{"key":"ref_17","first-page":"70","article-title":"Fractionated radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody","volume":"29","author":"Hanaoka","year":"2014","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1021\/acs.molpharmaceut.8b00027","article-title":"Bevacizumab radioimmunotherapy with accelerated blood clearance using the avidin chase","volume":"15","author":"Yudistiro","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jconrel.2022.10.032","article-title":"Delivery of aPD-L1 Antibody to i.p. Tumors via Direct Penetration by i.p. Route: Beyond EPR Effect","volume":"352","author":"Yamamoto","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105905","DOI":"10.1016\/j.esmoop.2025.105905","article-title":"First-in-human study of a thorium-227-labeled mesothelin-targeting antibody\u2013chelator conjugate (MSLN-TTC) in patients with malignant mesothelioma and other solid tumors","volume":"10","author":"Minchom","year":"2025","journal-title":"ESMO Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: A novel mesothelin-targeting antibody\u2013drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/cas.13979","article-title":"Therapeutic efficacy of radioimmunotherapy with yttrium-90\u2013labeled anti-podoplanin antibody NZ-12 for mesothelioma","volume":"110","author":"Sudo","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sudo, H., Tsuji, A.B., Sugyo, A., Kaneko, M.K., Kato, Y., Nagatsu, K., Suzuki, H., and Higashi, T. (2021). Preclinical evaluation of podoplanin-targeted alpha-radioimmunotherapy with the novel antibody NZ-16 for malignant mesothelioma. Cells, 10.","DOI":"10.21203\/rs.3.rs-691419\/v1"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2967\/jnumed.122.264979","article-title":"Evaluation of candidate theranostics for 227Th\/89Zr paired radioimmunotherapy of lymphoma","volume":"64","author":"Abou","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_25","first-page":"128","article-title":"Chemical design of radiolabeled antibody fragments for low renal radioactivity levels","volume":"59","author":"Arano","year":"1999","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jtcvs.2019.12.076","article-title":"Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts","volume":"160","author":"Chu","year":"2020","journal-title":"J. Thorac. Cardiovasc. Surg."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/501\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:15:59Z","timestamp":1773854159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ph19030501"],"URL":"https:\/\/doi.org\/10.3390\/ph19030501","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}